EXPLANATORY STATEMENT
STATUTORY RULES 1985 NO. 205
ISSUED BY AUTHORITY OF THE MINISTER FOR HEALTH
HEALTH INSURANCE ACT 1973
HEALTH INSURANCE REGULATIONS (AMENDMENT)
Sub-section 133(1) of the Health Insurance Act 1973 (‘the Act’) provides in part that the Governor-General may make regulations, not inconsistent with the Act, prescribing all matters required or permitted by the Act to be prescribed, or which are necessary or convenient to be prescribed for carrying out or giving effect to the Act.
Sub-section 19A(1) of the Act provides that, subject to sub-section 19A(2) of the Act, the regulations may provide that, unless the Minister otherwise directs, medicare benefits are not payable under the Act in respect of professional services rendered in prescribed circumstances.
Sub-section 19A(2) of the Act provides that regulations shall not be made for the purposes of sub-section 19A(1) except in accordance with a recommendation made to the Minister by the Medicare Benefits Advisory Committee under paragraph 67(1) (aa) of the Act. Paragraph 67(1)(aa) provides that included in the functions of the Medicare Benefits Advisory Committee, established under section 66 of the Act, is to
consider, in pursuance of a reference to it by the Minister for Health, whether medicare benefits should continue to be payable in circumstances specified by the Minister and to make recommendations arising from that consideration in writing to the Minister.
The Minister for Health accepted a recommendation of the Medicare Benefits Advisory Committee, made after consideration in pursuance of a reference to it by the Minister in accordance with paragraph 67(1)(aa) of the Act, that medicare benefits should not continue to be payable in respect of professional services which are rendered in association with the injection of human chorionic gonadotrophin (“HCG”) in the management of obesity.
Since 1954, claims have been advanced that the injection of HCG has therapeutic value in the treatment of obesity and the technique has been employed in Australia at various times by a small number of medical practitioners. The benefits which have been claimed include accelerated weight loss, and decreased hunger and discomfort during treatment. In 1976, however, the Australian Drug Evaluation Committee found that HCG had not been demonstrated to be an effective adjunctive therapy in the treatment of obesity, and that there was
no substantial evidence to support the various claims of its beneficial use in this regard. The Australian Drug Evaluation Committee is established by regulation pursuant to section 30 of the Therapeutic Goods Act 1966, one of its functions being to make medical and scientific evaluations of goods for therapeutic use. In its consideration, the Medicare Benefits Advisory Committee had regard, inter alia, to these findings; the views of the Endocrinology Unit, Royal Prince Alfred Hospital, Sydney; and the still unproven effectiveness of HCG in the management of obesity.
The regulation, which was made in accordance with the recommendation of the Medicare Benefits Advisory Committee, prescribes circumstances in which professional services are rendered in association with the injection of HCG in the management of obesity as circumstances for the purposes of sub-section 19A(1) of the Act in which medicare benefits are not payable.
The regulation came into operation on the date of its notification in the Commonwealth of Australia Gazette.
Overview
The Health Insurance Regulations (Amendment) Statutory Rules 1985 No. 205, issued under the authority of the Minister for Health, amends the Health Insurance Act 1973 to address the issue of the payment of Medicare benefits for professional services associated with the injection of human chorionic gonadotrophin (HCG) in the management of obesity. Enacted by the Parliament, the primary objective of this amendment is to align the payment of Medicare benefits with the prevailing scientific evidence and expert recommendations regarding the efficacy of HCG in treating obesity. The regulation, which came into effect on the date of its notification, was made following a recommendation from the Medicare Benefits Advisory Committee, which concluded that there was insufficient evidence to support the therapeutic use of HCG for obesity management. This legislative amendment ensures that Medicare benefits are not payable for professional services related to HCG injections for obesity, thereby reflecting the current understanding of its effectiveness.
Scope and Application
The Health Insurance Act 1973, as amended by the Health Insurance Regulations (Amendment) Statutory Rules 1985 No. 205, applies to individuals and entities involved in the provision of health services within Australia. Specifically, the regulation targets professional services rendered in association with the injection of human chorionic gonadotrophin (HCG) for the management of obesity, ensuring these services are not eligible for medicare benefits. This amendment was made in response to a recommendation by the Medicare Benefits Advisory Committee, which considered the findings of the Australian Drug Evaluation Committee and expert opinions from the Endocrinology Unit at Royal Prince Alfred Hospital. The regulation applies nationally and is intended to align with the Act's stipulations, thereby excluding certain professional services from medicare benefits unless otherwise directed by the Minister. The scope of the regulation is limited to professional services related to HCG injections for obesity management, and its implementation reflects a national policy decision regarding the provision of health benefits.
Key Provisions
The Health Insurance Regulations (Amendment) specify that medicare benefits will no longer be payable for professional services rendered in association with the injection of human chorionic gonadotrophin (HCG) in the management of obesity, in accordance with sub-section 19A(1) of the Health Insurance Act 1973. This decision is based on a recommendation from the Medicare Benefits Advisory Committee, as outlined in paragraph 67(1)(aa) of the Act, which was accepted by the Minister for Health. This regulation was enacted following the findings of the Australian Drug Evaluation Committee, which in 1976 determined that there was insufficient evidence to support the use of HCG as an effective therapy for obesity. Consequently, these regulations effectively disallow the payment of medicare benefits for services related to the administration of HCG for weight management purposes.
Entities and individuals affected by these regulations, such as medical practitioners and patients, must adhere to the stipulations that prohibit medicare benefits for HCG-related services in the context of obesity management. This means that any professional services rendered in association with the injection of HCG for weight loss will not be eligible for reimbursement under the Act. Medical practitioners must ensure that they are not billing for these services as medicare benefits, and patients should be informed of the implications regarding their treatment costs and coverage.
Failure to comply with these regulatory provisions may result in civil or criminal consequences. Specifically, providers who continue to bill for these services as medicare benefits could face penalties. Under the Health Insurance Act 1973, there are stipulated maximum penalties for non-compliance, which could include fines and other legal repercussions. Additionally, repeated or intentional breaches may lead to more severe consequences, including potential criminal charges for fraud or misrepresentation. It is crucial for all parties involved to understand and comply with these regulations to avoid any legal issues.